Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report) gapped down prior to trading on Wednesday . The stock had previously closed at $15.21, but opened at $14.21. Tonix Pharmaceuticals shares last traded at $16.27, with a volume of 515,692 shares trading hands.
Wall Street Analysts Forecast Growth
Separately, StockNews.com started coverage on Tonix Pharmaceuticals in a research report on Monday. They set a "sell" rating for the company.
View Our Latest Report on TNXP
Tonix Pharmaceuticals Stock Performance
The stock's 50 day moving average is $29.63 and its two-hundred day moving average is $25.95. The firm has a market capitalization of $22.33 million, a P/E ratio of 0.00 and a beta of 2.07. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81.
Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($23.00) EPS for the quarter, beating the consensus estimate of ($203.00) by $180.00. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The company had revenue of $2.82 million during the quarter, compared to analysts' expectations of $2.63 million. As a group, equities analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -1762.5 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Tonix Pharmaceuticals
A hedge fund recently bought a new stake in Tonix Pharmaceuticals stock. PFG Investments LLC acquired a new position in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 218,003 shares of the company's stock, valued at approximately $72,000. PFG Investments LLC owned 0.12% of Tonix Pharmaceuticals at the end of the most recent quarter. Institutional investors own 82.26% of the company's stock.
Tonix Pharmaceuticals Company Profile
(
Get Free Report)
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
Read More
Before you consider Tonix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tonix Pharmaceuticals wasn't on the list.
While Tonix Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
